Education
About Us
Working with TipRanks
Follow Us
Fluicell AB (DE:5J90)
:5J90
5J90 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.67 - €1.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.00
Market Cap
€1.03M
Enterprise Value€1.28M
Total Cash (Recent Filing)€9.71M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta22.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,373,703
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio2.39
Price to Book (P/B)155.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was €0.67 and its highest was €1.61 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is €1.03M.
When is Fluicell AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fluicell AB’s earnings last quarter?
Currently, no data Available
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in DE:5J90
Company Description
Fluicell AB
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.
Technical Analysis
OncoZenge AB
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
AcouSort AB
―